Praxis Precision Medicines
PRAX
152 hedge funds and large institutions have $1.31B invested in Praxis Precision Medicines in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 45 reducing their positions, and 19 closing their positions.
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
31% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 45
29% more capital invested
Capital invested by funds: $1.02B → $1.31B (+$292M)
20% more call options, than puts
Call options by funds: $27.3M | Put options by funds: $22.7M
6% more funds holding
Funds holding: 143 → 152 (+9)
19.93% less ownership
Funds ownership: 118.57% → 98.64% (-20%)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$39.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$19.4M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$18M |
| 5 |
Goldman Sachs
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$30.3M |
| 2 |
Morgan Stanley
New York
|
-$28.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$22.8M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.5M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$12M |
PRAX Hedge Fund Activity: Q3 2025 in Review
152 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2025, worth a combined $1.31B — up 29% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PRAX positions and 19 closed out — a net gain of 9 holders — while 59 added to existing stakes and 45 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $39.4M. The largest seller was Cormorant Asset Management, cutting an estimated $30.3M.
- 152 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2025, up from 143 in Q2 2025.
- Funds reported $1.31B of Praxis Precision Medicines stock for Q3 2025, up 29% quarter-over-quarter.
- 28 funds opened new Praxis Precision Medicines positions in Q3 2025 and 19 closed out, a net change of +9 holders.
- The largest Praxis Precision Medicines buyer in Q3 2025 was Perceptive Advisors, an estimated $39.4M added.
- The largest Praxis Precision Medicines seller in Q3 2025 was Cormorant Asset Management, an estimated $30.3M sold.
Based on aggregated 13F filings for Q3 2025.